熱門資訊> 正文

Kyverna Therapeutics任命Greg Martini为首席财务官

2026-05-18 20:16

Ironwood醫藥(IRWD) 0

Kyverna Therapeutics (KYTX) said on Monday it appointed Greg Martini as chief financial officer as the company prepares for a potential commercial launch of its autoimmune disease cell therapy candidate miv-cel.
Martini joins Kyverna from Ironwood Pharmaceuticals (IRWD), where he served as senior vice president and CFO.
He succeeds Marc Grasso, who will remain with the company in a consulting role during the transition.
Kyverna is advancing miv-cel, also known as KYV-101, toward a potential first approval in stiff person syndrome.

More on Kyverna Therapeutics

Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis
Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Kyverna begins rolling BLA submission for miv-cel
Kyverna rises on new mid-stage trial data for myasthenia gravis therapy

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。